Immune checkpoint modulation: Rational design of combination strategies-Reference-Cited by-同舟云学术

Immune checkpoint modulation: Rational design of combination strategies

Published:2015-06 Issue: Volume:150 Page:23-32
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Zamarin Dmitriy,Postow Michael A.

Funder

Bristol-Myers Squibb

Conquer Cancer Foundation

Damon Runyon Cancer Research Foundation

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference144 articles.

1. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma;Advani;J Clin Oncol,2009

2. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC);Amin;J Clin Oncol,2014

3. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice;Amos;Cancer Immunol Immunother CII,2011

4. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma;Andtbacka;J Clin Oncol,2013

5. CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma;Andtbacka;J Clin Oncol,2014

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress;Frontiers in Pharmacology;2024-06-18

2. Phytochemicals in regulating PD‐1/PD‐L1 and immune checkpoint blockade therapy;Phytotherapy Research;2023-12-05

3. Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients;Neoplasia;2023-11

4. In Silico design and characterization of RAD51 protein inhibitors targeting homologous recombination repair for cancer therapy;Genome Instability & Disease;2023-09-20

5. Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment;Clinical and Experimental Medicine;2023-04-06